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Background and objective
The hepatocellular carcinoma (HCC) is a frequent cancer
worldwide. This disease is more frequent in patients over
70 years and only few papers in literature analyze the clin-
ical characteristics and the survival of elderly patients with
HCC. The aim of this study is to describe the features and
the results of treatment of patients older than 80 years
with HCC.
Methods
464 patients with HCC observed from 1991 to 2007 were
included into the study. All the patients were evaluated for
treatment of HCC in relation to the severity of liver
impairment and tumor stage. All the patients included
into the study had no evidence of distant metastases. We
compared the clinical characteristics and results in
patients older or younger than 80 years.
Results
Of the 464 patients included into the study 414 were
younger than 80 and 50 older than 80 years. Median fol-
low up time for surviving patients was 25 months (range
1–155). 283 patients were in Child-Pugh class A, 161 in
class B and 20 in class C. 271 patients had single HCC and
293 patients had multiple HCCs. 183 patients had HCC
smaller than 3 cm, 121 larger than 3 cm and smaller than
5 cm and 105 larger than 5 cm. The severity of liver disease
and the tumor stage was not significant different among
patients younger or older than 80 years. 136 (29.2%)
patients were submitted to liver resection (LR), 232
(50.0%) to local ablative therapies (LAT) (ethanol injec-
tion, radiofrequency ablation, chemoembolization), 8
(1.7%) to liver transplantation (LT) and 88 (19.0%) to
supportive therapy (ST). Median survival time for all
patients was 30.4 months (95% CI 24–36). Overall sur-
vival was not significantly different in the group younger
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or older then 80 years with an actuarial 5-year survival of
27% and 25%, respectively. Median survival time was 57
months for LR, 30 for LAT and 8 for ST, with a 5-year sur-
vival of 47%, 20% and 2.5% respectively (p = 0.001). In
the LR, LAT and ST survival was not significantly different
if the two group of patients, younger and older than 80
years (Figures 1, 2).
Conclusion
The present study shows that LR and LAT for patients with
HCC older than 80 years can achieve good results that are
comparable to younger patients. Advanced age should not
be considered a contraindication for LAT or LR of HCC;
optimal treatment strategy should not be guided by
patients' age but by the tumor stage and the degree of liver
dysfunction.
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